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OBJECTIVES: Improved peri- and postoperative clinical outcomes can result in 
economic savings for hospitals and payers. While the relative effectiveness of 
topical hemostatic agents in the termination of bleeding during cardiac 
operations has been demonstrated, the economic benefit has not been 
evaluated. An economic analysis quantified the reduction in costs associated 
with efficient control of intraoperative bleeding. METHODS: Based on a cost-
consequence framework, an economic model computed incremental annual 
outcomes and cost savings from use of a Hemostatic Matrix (FLOSEAL) versus 
other topical hemostatic agents. The model captured cost implications of 
acquisition, operating room time, complications, blood transfusions and surgical 
revisions due to bleeding associated with cardiac surgery procedures. Clinical 
outcomes data were from a prospective controlled study evaluating whether the 
use of a Hemostatic Matrix correlates to a decrease in postoperative bleeding-
related events and complications relative to a control group using other 
hemostatic agents in a cohort of mixed-cardiothoracic aortic procedures (Nasso 
et al., 2009). Base-case costs, expressed in 2012 USD, were obtained through US 
cost database analyses and literature. Surgery and care related costs were 
regionally adjusted by economically influenced wage indices. Cost savings were 
determined based on a hypothetical annual number of cases. RESULTS: Effective 
hemostasis with a Hemostatic Matrix, when compared with a control group, 
results in cost savings through reduced OR time, reduced need for surgical 
revision, fewer blood transfusions and fewer post-operative complications. For a 
facility that conducts 600 cardiac surgeries annually, the net annualized cost 
savings is $5.2 million with the reduction in complications contributing the 
largest portion of the savings. CONCLUSIONS: The present economic model is 
reliable in evaluating hospital cost fluctuations associated with the use of 
hemostatic agents in cardiac surgery. These analyses strongly indicate 
significant savings if the Hemostatic Matrix is routinely employed in a cohort of 
mixed cardiothoracic aortic surgical procedures.  
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OBJECTIVES: Transcatheter radiofrequency ablation (RFA) is one of the primary 
treatments for symptomatic drug-refractory atrial fibrillation (AF) and it is 
considered the first-line therapy for other arrhythmias. One of the major 
complications of procedure is cardiac perforation and tamponade, which can 
occur in cardiac chambers. Contact force technology is an important predictor of 
RFA efficacy and safety, a cost-consequence analysis between standard ablation 
catheter and Thermocool®SmartTouch™ catheter for RFA of AF has been 
developed in order to evaluate the introduction of the contact force in clinical 
practice of Terni’s hospital. METHODS: An excel model was developed to 
simulate a cost-consequence analysis based on literature review and 
economic/organizative data collection. The means, standard deviation and 95% 
confidence intervals for the analysis were estimated using Bayesian methods 
(10,000 simulations) and assuming a reduction in terms of procedure time, 
complications and recurrence with the use of Thermocool®SmartTouch™ 
catheter. The analysis estimated the cost per procedure and per patient from 
hospital perspective in 1 year time horizon. RESULTS: The average total cost 
(including consumables, room, personnel and complications costs) was 
estimated at 9,201€ (95%IC 7,629-11,251€) for Thermocool® SmartTouch™ 
procedure and 9,460€ (95%IC 7,885-11,577€) for standard procedure. The 
consequences were estimated as procedure cost per patient, assuming the re-
treatment reduction with Thermocool® SmartTouch™. The procedure cost per 
patient was estimated at 11,501€ (95%IC 9,234-14,602€) with Thermocool® 
SmartTouch™ and at 13,515€ (95%IC 10,883-17,324€) with standard. Moreover, 
both procedure and fluoroscopy time have been calculated respectively: 199 and 
40 minutes for Thermocool®SmartTouch™ catheter vs 284 and 57 minutes for 
standard catheter. CONCLUSIONS: Thermocool® SmartTouch™ technology 
appears cost-savings and the consequences management results to be favorable. 
The results were consistent according to the developed probabilistic sensitivity 
analysis, but they could be different in real clinical practice, therefore it is 
necessary to collect data after Thermocool® SmartTouch™ introduction for 
validating the results simulated.  
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OBJECTIVES: To determine the cost-effectiveness of using a platelet reactivity 
assay (PRA) to aid in the selection between dual antiplatelet treatment strategies 
for acute coronary syndrome (ACS) patients. METHODS: A hybrid decision 
tree/Markov model was used to calculate 5-year costs (2011 US$), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) of 
1-year of universal clopidogrel, ticagrelor or prasugrel (given to all patients) or 
PRA-driven ticagrelor or prasugrel (given to patients with high platelet reactivity 
defined as >230 on the VerifyNow P2Y12 assay, others got generic clopidogrel). 
We assumed a cohort of 65-year-old ACS patients and 32% and 13% incidences of 
high platelet reactivity ~24-48 hours post-revascularization and at 1-month. The 
analysis was conducted from a US payer perspective and used a 1-year cycle 
length. Data depicting the efficacy and safety of dual antiplatelet treatment were 
taken from randomized trials. RESULTS: The PRA-driven ticagrelor and prasugrel 
strategies were cost-effective compared to universal clopidogrel (ICERs=$40,100 
and $49,143/QALY); however, universal ticagrelor and prasugrel strategies were 
not (ICERs=$61,651 and $96,261/QALY). Monte Carlo simulation suggested PRA-
driven ticagrelor, PRA-driven prasugrel, universal ticagrelor and universal 
prasugrel would have ICERs<$50,000/QALY (be cost-effective) in 52%, 40%, 23%, 
and 2% of 10,000 iterations versus universal clopidogrel. Universal ticagrelor or 
prasugrel were also not found to be cost-effective strategies compared to the 
PRA-driven use of these same agents (ICERs=$68,182 and $116,875/QALY, 
respectively). Monte Carlo simulation suggested universal selection of ticagrelor 
and prasugrel would have ICERs<$50,000/QALY in only 26% and 4% of 10,000 
iterations compared to their PRA-driven use. The model’s conclusions were most 
sensitive to differences in antiplatelet agent costs and drug-specific relative risks 
of death. CONCLUSIONS: Even in the age of generic clopidogrel, PRA-driven 
selection of antiplatelet therapy appears to be a cost-effective strategy with the 
potential to decrease overall ACS associated health care costs.  
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OBJECTIVES: Ticagrelor has been shown to reduce acute coronary syndrome 
(ACS)-related complications, but with a higher incidence of bleeding and greater 
acquisition cost than generic clopidogrel. This study was designed to assess the 
cost-effectiveness of ticagrelor use compared with clopidogrel in ACS patients 
from the US health system perspective. METHODS: A decision model was 
developed and the probabilities of complications including myocardial infarction 
(MI), ischemic stroke (IS), vascular death, and major bleeding events were 
defined based on the Platelet Inhibition and Patient Outcomes (PLATO) trial and 
sub studies. Cost inputs were identified from a systematic literature review and 
from Healthcare Cost and Utilization Project (HCUP) databases. Life expectancy 
for PLATO population was estimated using DEALE method. All costs were 
adjusted to 2012 US dollars. Utility estimates for complications were identified 
from peer reviewed studies, and quality-adjusted life years (QALYs) were 
projected to measure effectiveness. Lifetime costs and cost-effectiveness were 
calculated. One-way sensitivity analyses were performed on all variables. 
RESULTS: In the base case analysis, ticagrelor treatment ($58,922.91 and 10.2579 
QALYs) provided 0.1243 more QALYs but cost $23,566.60 more than clopidogrel 
($35,366.30 and 10.1336 QALYs). The incremental cost-effectiveness ratio (ICER) 
for the ticagrelor treatment was $189,468.79/QALY. Results were sensitive to the 
cost (50% to 200% range) of ticagrelor ($57,167.95 to $454,066.84 per QALY), the 
cost of clopidogrel ($228,166.51 to $112,069.80 per QALY), and the hazard ratio 
(95% confidence interval range) of vascular death ($135,710.24 to $358,837.65 per 
QALY). The ICER was less than $100,000/QALY only if the daily acquisition cost of 
ticagrelor was lower than $4.88 (i.e., about 66% of the daily cost in the base case). 
CONCLUSIONS: At its current price, ticagrelor was not a cost-effective treatment 
strategy in patients with ACS compared to generic clopidogrel, using either 
$50,000 or $100,000/QALY as the ICER threshold.  
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OBJECTIVES: Type-2 diabetes in France has increased in prevalence over the past 
decade and there is a need to examine cardiovascular outcomes based on real-
world evidence (RWE). The CANARD model was developed to evaluate the cost-
effectiveness (CE) of treatments using data from a RWE French population in the 
IMS LifeLinkTM Diabetes Cohort database. METHODS: A Markov micro-simulation 
model was developed in Microsoft Excel 2007® using the United Kingdom 
Prospective Diabetes Study (UKPDS) risk equations to predict cardiovascular 
outcomes (MI, stroke, death). Four treatment pathways taken from the IMS 
LifeLinkTM Diabetes Cohort database were evaluated, which included step-wise 
treatment switches based on the patient’s HbA1c. Treatments within the 
pathway included diet and exercise, metformin (MF), oral anti-diabetics (OADs) 
of sulfonylurea (SU) or dipeptidyl peptidase IV (DDP-IV) in addition to MF, a lipid 
lowering agent (atorvastatin) in addition to MF and an OAD, and insulin. CE 
outcomes in 13 subgroups were explored and uncertainty in the model was 
evaluated with a probabilistic sensitivity analysis (PSA) and expected value of 
perfect information (EVPI). The model was validated by comparing the predicted 
results to the database results at 18 months. RESULTS: The results showed that 
the treatment pathway including SU with atorvastatin was the most cost-
effective in the general population at €2,640/QALY. The results from the PSA 
showed that the likelihood of this treatment pathway being cost-effective was 
0.61 at willingness-to-pay (WTP) of €20,000/QALY, and 0.56 at a WTP of 
€50,000/QALY. EVPI at a WTP of €20,000/QALY and €50,000/QALY were €476 per 
patient and €1,427 per patient respectively. The subgroup results demonstrated 
that depending on the WTP of the French National Health Service, several 
treatments pathways may be CE. CONCLUSIONS: Overall, SU with atorvastatin 
was the most cost-effective treatment for a French type II diabetic population, 
however, uncertainty was evident and therefore, future research would be of 
value.  
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OBJECTIVES: Hypertension, the leading risk factor for global disease burden, 
affects 20% of Canadians. Approximately 10-15% of hypertensive patients are 
treatment resistant. Controlled clinical trial data demonstrate that catheter-
based renal denervation (RDN) leads to clinically significant blood pressure 
reductions of 32/12 mmHg in treatment resistant patients. The goal of this study 
was to predict the long-term risk reduction and the lifetime cost-effectiveness of 
RDN in a Canadian setting. METHODS: A Markov model with monthly cycles was 
used to estimate: a) ten-year relative risks for clinical endpoints and lifetime 
costs; b) unadjusted and quality-adjusted life expectancy (LYs and QALYs); and c) 
the incremental cost-effectiveness ratio (ICER) of RDN compared to optimal 
pharmacotherapy (OPT) from a Canadian provincial health care system 
perspective. Transition probabilities were based on multivariable risk equations 
(including Framingham) and clinical inputs were based on the Symplicity HTN-2 
trial cohort characteristics. Cost data and utility scores were derived from 
published literature and provincial public databases. The clinical endpoints 
modeled were stroke, myocardial infarction (MI), all coronary artery disease 
(CHD), heart failure (HF), and end-stage renal disease (ESRD). Costs, life 
expectancy, and ICERs were discounted at 3%, and sensitivity and threshold 
analyses were conducted. RESULTS: The 10-year relative risks for RDN versus 
OPT were: stroke 0.70, MI 0.68, all-CHD and HF 0.78, respectively, and ESRD 0.72. 
The lifetime costs of OPT and RDN were $62,076 and $65,471, respectively. RDN 
increased QALYs by 0.60 and LYs by 0.65 compared to OPT. ICERs for RDN were 
$5,648 /QALY and $5,171/LY. Considering willingness-to-pay thresholds of 
$25,000 and $50,000/QALY, RDN was cost-effective down to effect sizes of 18.2 
and 12.2 mmHg systolic blood pressure reductions, respectively. CONCLUSIONS: 
Catheter-based renal denervation, across a wide spectrum of assumptions, is a 
cost-effective option for the treatment of resistant hypertension patients in 
Canada.  
 
PCV76  
COST-EFFECTIVENESS OF TICAGRELOR VERSUS GENERIC CLOPIDOGREL IN 
PATIENTS WITH ACUTE CORONARY SYNDROMES IN CANADA  
Grima DT1, Brown ST1, Kamboj L2, Bainey K3, Goeree R4, Oh P5, Ramanathan K6, Goodman S7 
1Cornerstone Research Group, Burlington, ON, Canada, 2AstraZeneca Canada, Mississauga, ON, 
Canada, 3Mazankowski Alberta Heart Institute / University of Alberta Hospital, Edmonton, AB, 
Canada, 4PATH Research Institute, McMaster University, Hamilton, ON, Canada, 5University 
Health Network, Toronto, ON, Canada, 6St. Paul's Hospital, Vancouver, BC, Canada, 7St. 
Michael's Hospital, Toronto, ON, Canada  
OBJECTIVES: Ticagrelor showed a significant reduction in major cardiac events 
in patients with acute coronary syndrome (ACS) compared with clopidogrel in 
the Platelet Inhibition and Patient Outcomes (PLATO) trial. Our aim was to assess 
the cost-effectiveness of ticagrelor compared to brand and generic clopidogrel in 
ACS patients from the perspective of the publically funded Canadian health care 
system. METHODS: A two-part model was developed consisting of a one-year 
decision tree and a lifetime Markov model. Within the decision tree, patients 
remained event-free, experienced a non-fatal myocardial infarction (MI), a non-
fatal stroke, or death due to vascular or non-vascular related causes based on 
data from the PLATO trial. The lifetime Markov model followed these patients 
and allowed subsequent MI, stroke and death. Patient level EQ5D (utility) and 
resource use were derived from PLATO. Transition probabilities and Canadian 
unit costs specific were derived from published sources. Univariate and 
probabilistic sensitivity analyses were conducted. RESULTS: In the base case 
analysis, one-year of treatment with ticagrelor post-ACS resulted in a lifetime 
incremental cost-effectiveness ratio (ICER) of $9,745 per quality adjusted life year 
(QALY) gained, assuming the generic cost for clopidogrel. Compared to brand 
clopidogrel, the ICER was $1,523 per QALY gained. A probabilistic sensitivity 
analysis demonstrated a 93% probability of being below $20,000 per QALY gained 
and a 99% probability of being below $30,000 per QALY gained. CONCLUSIONS: 
Ticagrelor is a clinically superior and cost-effective option compared to brand 
and generic clopidogrel for the prevention of major cardiovascular events among 
ACS patients in Canada. These results strongly support the reimbursement of 
ticagrelor for this indication.  
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OBJECTIVES: Severe Aortic stenosis (AS) refers to pathological, clinical and 
pathophysiological changes associated with decreased aortic valve area, as a 
consequence of calcification. Transcatheter Aortic Valve Implantation (TAVI) –is 
targeted at individuals deemed unsuitable candidates for Surgical Aortic Valve 
Replacement (SAVR) as an alternative to Medical Management (MM). Recently 
published studies have demonstrated TAVI to be a good use of health care 
resources in other countries. Our primary objective was to estimate the cost-
effectiveness of TAVI for AS compared with MM in Colombia. METHODS: We 
used an Excel-based probabilistic decision analytic model to evaluate the cost-
effectiveness of TAVI for AS compared to MM. A 3 year update of the landmark 
PARTNER B randomized study was used to inform treatment specific mortality. 
Rates for adverse events and pacemaker use were taken from a large 
multinational registry. Model inputs included costs and resource use for 
inpatient and outpatient treatment in Colombia, and were taken from the 
published literature and local sources. Utilities and quality of life were estimated 
from the PARTNER B study. Additional parameters on local epidemiology were 
obtained from international peer-reviewed literature and private and public 
official databases. Cost-effectiveness was assessed from a third-payer 
perspective and over a 20-year time horizon. RESULTS: Our discounted results 
show that over a patients lifetime, individuals on TAVI obtained 2.55 QALYs and 
those on MM, 0.83 QALYs. The associated lifetime costs for both interventions 
were COP$92 million and COP$8 million for TAVI and MM respectively. The 
incremental cost-effectiveness ratio was therefore $49 million per QALY gained. 
Although TAVI costs were much higher than MM, TAVI improved the probability 
of survival by 12%, resulting in an expected survival gain of 1.25 years. 
CONCLUSIONS: This analysis suggests that TAVI is a cost-effective alternative 
for the treatment of AS in patients unsuitable for SAVR in Colombia.  
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban relative to 
warfarin, for the prevention of stroke in patients with AF. METHODS: A Markov 
model demonstrating the progression of AF patients from healthy state towards 
embolic and bleeding events and to death was adapted to the Turkish setting. 
The cycle length was set as three-months. The analysis was undertaken from a 
payer perspective. Event rates and treatment effects were derived from the 
ROCKET AF clinical trial. Utility values for events were based on international 
literature. Costs of each health state included year 2012 local costs of 
medications, monitoring and events (Mid-2012 USD currency rate was used). 
Incremental cost effectiveness ratios (ICER) per life year (LY) and quality-
adjusted LY (QALY) gained were calculated. One-way sensitivity analyses were 
conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. 
Willingness-to-pay (WTP) threshold was set as twice the local gross domestic 
product per capita (US$20,888). RESULTS: The total cost of rivaroxaban-treated 
patients was US$1,065 higher compared to warfarin. Additional drug acquisition 
costs (US$3,083) caused by rivaroxaban were mainly offset by reduced 
monitoring (US$1,902) and event costs (US$116). Moreover, rivaroxaban was 
associated with increments of 0.065LYs and 0.055QALY leading to an ICER of 
US$16,362/LY gained and US$19,500/QALY gained. Sensitivity analyses showed 
that the cost-effectiveness results are fairly insensitive to most inputs. The 
changes in the cost of embolic and hemorrhagic events had almost no effect on 
ICER values. The ICER value was sensitive to the cost and frequency of 
monitoring in warfarin patients. CONCLUSIONS: Rivaroxaban, with its cost-
saving effect on monitoring, reducing the frequencies of clinical events, 
improvement in LYs and QALYs, and ICER values below WTP threshold, is 
suggested to be a cost-effective alternative for the prevention of stroke in AF.  
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OBJECTIVES: Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, represents 
a new OAC option for stroke prevention in patients with non-valvular atrial 
fibrillation (AF). The objective of this study was to assess the cost effectiveness of 
rivaroxaban in three European countries. METHODS: Markov models for Greece, 
Spain and Slovakia were developed to estimate the cost-effectiveness of 
rivaroxaban and vitamin K antagonist (VKA) treatment from the payer 
perspective of each country. In all three models, baseline event rates (adjusted to 
three month cycles) and relative treatment effects (HRs) were derived from the 
safety on treatment analysis of the ROCKET AF study and available literature. 
Utility values for events used to estimate the quality adjusted life years (QALY) 
were based on literature. Each model used costs and other economic inputs 
specific for that country. One-way and probabilistic sensitivity analyses (PSA) 
were performed. A subpopulation analysis was also conducted for Greece and 
Spain comparing rivaroxaban with VKA in patients with poor INR control 
(patients who spend less than 65% of time in therapeutic range). PSA were also 
performed to assess the robustness of the findings. RESULTS: Base-case analyses 
indicated that rivaroxaban was cost-effective with ICERs of €4,517, €17,432 and 
€11,274 per QALY compared with adjusted-dose warfarin for Greece, Slovakia 
and Spain, respectively. Rivaroxaban was found to be cost-effective in at 
willingness-to-pay thresholds for each country. The analyses conducted for 
patients with poor INR control found that rivaroxaban dominated VKA in this 
patient population in Greece, whereas an ICER of €2144 per QALY compared with 
VKAs were seen in Spain. PSA confirmed the robustness of the results. 
CONCLUSIONS: Rivaroxaban is a cost-effective alternative to VKAs for the 
prevention of stroke in patients with AF, particularly for those patients with poor 
INR control.  
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